|Articles|January 3, 2014

Best of Blog: Most Read Stories of 2013

Our most read stories of 2013.

We hope everyone had a lovely holiday and a very happy new year celebration! We at Applied Clinical Trials want to thank you for your support in 2013, and we're looking forward to sharing an exciting 2014.To help ease back into things following the holiday, we've compiled a look back on our most popular blogs of 2013, in case you might have missed any.

Tips on Writing Risk-Based Monitoring Plans

Future Clinical Trials Are Here and How They May Succeed

How CRO Worldwide Clinical Trials is Approaching eTMF

FDA Updates Current Thinking on Risk-Based Monitoring

Clinical Trials Are Slow at Adopting Change

Future Clinical Trials: How Pharmacies will Transform Clinical Research

The First FDA-Approved Crowdsourced Protocol: An Interview with Tomasz Sablinski, MD, PhD

What Do Risk-Based Monitoring and Patient Engagement Have in Common?

2013 Predictions for Clinical Development

The Gamification of Clinical Trials: What's Next?

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 25th, 2026

Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It

Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems and lack an audit trail, requiring sponsors to document oversight as a connected operating system with clear decision records, escalation pathways, and issue resolution from start to finish.

September 25th, 2026

How AI Is Changing Endpoint Selection Before a Trial Even Starts

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection beyond the bounded experience of a single sponsor team—and surfacing options that traditional design thinking might never have considered.

September 25th, 2026

ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy

In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.

© putilov_denis - © putilov_denis - stock.adobe.com

September 24th, 2026

When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny

In rare disease drug development where no registry or natural history dataset exists, real-world evidence quality depends on treating evidence engineering as a design-stage decision, defining intended regulatory use and standardizing endpoints, harmonization, and data provenance upfront rather than reconciling gaps after collection.

September 24th, 2026

Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif

In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site interaction more effective, and where the industry is still falling short in its push toward patient-centered trial design.

September 24th, 2026

ACT Brief: Data Provenance and Device Strategy, Cell-Gene Therapy Site Readiness, and Data Harmonization Bottleneck

In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.

September 23rd, 2026

Clinical Site Readiness for Cell and Gene Therapies: Operational and Supply Chain Challenges as they Scale and as they Expand into the Community Care Setting

Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to manufacturing capacity, requiring standardized processes, digital integration, and distributed logistics networks.

September 23rd, 2026

Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials

In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.

Best of Blog: Most Read Stories of 2013

Related to this article

Trending on Applied Clinical Trials Online

When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny

ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy

Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development

How AI Is Changing Endpoint Selection Before a Trial Even Starts

Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif